Tinninus Assessment Technology

MENODYS announces the recruitment of the last patient in a proof of concept comparing its Tinnitus Assessment Technology to the current standard method of evaluating tinnitus

Longueuil, Quebec, Canada – Pr. Sylvie Hébert of the School of Speech Pathology and Audiology at the University of Montreal has completed the recruitment of a proof of concept named MENODYS-INNOV, a research project comparing an innovative technological approach for the objective assessment of tinnitus developed by MENODYS to the standard currently used method of psychoacoustic pitch and loudness measurement used by audiology clinicians around the world. 31 patients with established diagnosis of bilateral tinnitus for at least 6 months were evaluated twice (2 visits) separated by 30 days by 2 different audiologists using during each visit, 2 different methods of evaluation of the tinnitus pitch and loudness. The study objectives are as follow: 1) demonstrating the advantage of the MENODYS tinnitus evaluation method to objectively assess tinnitus in pitch and loudness; 2) demonstrating the advantage of the MENODYS tinnitus evaluation method in terms of time requirement (speed of the test) for the audiologist and the patient; 3) demonstrating the value of assessing high frequencies (above 8000 Hz) in tinnitus assessment procedures; 4) demonstrating the value of the MENODYS tinnitus evaluation method for its capacity to define the best tinnitus symptom attenuation protocol (better adjustment of hearing aids and sound generators); and 5) demonstrating the value of the MENODYS tinnitus evaluation method in terms of test-retest accuracy (a tool to follow–up patients over time on the benefits of tinnitus symptoms attenuation protocols).

“This study was launched to demonstrate the importance for audiology professionals around the world, dealing with tinnitus patients, to have access to a rapid, objective, reproducible, and precise tinnitus assessment technology”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important and growing worldwide health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Tinninus Assessment Technology

MENODYS announces the publication in Frontiers in Neurology of the clinical validation results of its Tinnitus Assessment Technology

Longueuil, Quebec, Canada – MENODYS announces that the results of the clinical validation of its tinnitus assessment technology (TAT) have been accepted for publication in the February 2017 edition of the journal “Frontiers in Neurology”. Invented by Pr. Sylvie Hébert and Mr. Philippe Fournier of the School of Speech Pathology and Audiology at the University of Montreal, the TAT offers audiology specialists around the world a rapid and innovative approach to objectively assess the frequency and amplitude of their patient’s tinnitus. Current clinical assessment of tinnitus relies mainly on self-report. Psychoacoustic assessment of tinnitus pitch and loudness are recommended but methods yield variable results. The published results report that a previously validated fixed laboratory-based method and a newly developed clinically-relevant portable prototype (MENODYS TAT) yield comparable results in the assessment of psychoacoustic tinnitus pitch and loudness. The clinical validation identified that despite differences in the devices’ physical presentations, likeness and loudness ratings were globally consistent between the two methods and, moreover, highly reproducible from one method to the other on the subjects tested. All in all, both methods yielded robust tinnitus data in less than 12 minutes, with the MENODYS TAT having the advantage of not being dependent of learning effects, being user-friendly, and being adaptable to the audiogram of each patient to further reduce testing time.

“This publication confirms the successful transformation of a University-based concept into a commercially ready medical technology that will modify the way patients with tinnitus can precisely define the nature of their tinnitus in both frequency and loudness, in less than 12 minutes. The MENODYS TAT thus offers an innovative tool for audiology specialists to objectively define tinnitus and follow up regularly on the benefit of the prescribed tinnitus symptom attenuation protocol”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Sterile saline slush making apparatus

MENODYS announces the first successful use of the Sterile Saline Slush Making Apparatus in an organ collection procedure

Longueuil, Quebec, Canada – MENODYS is proud to announce that the Beta Prototype of the Sterile Saline Slush Making Apparatus (SSSMA) enabled for the first time, in an operating procedure at the Sacré-Coeur Hospital Organ Collection Center in Montreal, Quebec, Canada, the automated production of large volumes of sterile saline slush for the preservation of human organs.

Invented by Dr Pierre Marsolais, internal medicine specialist, intensivist and coordinator of the Organ Collection Center of the Sacré-Coeur Hospital of Montreal, this patent pending medical technology developed jointly with MENODYS accomplished its purpose in answering an important unmet need in organ collection and transplant procedures, the preparation of large volumes of sterile saline slush.

“ We are extremely pleased with the first results obtained with the SSSMA Beta Prototype particularly in regards to the quality of the “slush” that was generated without the need of human intervention in its production. This innovative medical technology will clearly answer the needs of numerous hospitals around the world involved in organ collection and transplantation that are looking for solutions to optimize production of large volumes of sterile saline slush for human organ preservation procedures ” said Richard Côté, Executive Vice-President of MENODYS.

About MENODYS

MENODYS is a Canadian company specialized in the research, development and commercialization of medical technologies. www.menodys.com

 

LT10 Surgical Magnetic Mat

A publication in BioMedical Engineering OnLine demonstrates the safety benefit of using the LT10G Surgical Magnetic Mat of MENODYS in preventing magnetic interferences on a pacemaker in comparison to 4 other commercially available products

Longueuil, Quebec, Canada – Zaphiratos et al. published an article in BioMedical Enginnering OnLine (BioMed Eng OnLine 2016 15:83) entitled: “Interference between surgical drapes and pacemakers: an observational study comparing commercially available devices and a new magnetic isolated drape”, the LT10G Surgical Magnetic Mat from MENODYS. The paper concludes that when the LT10G Surgical Magnetic Mat is used, it does not cause magnetic interference in all patients when placed over the pacemaker. In comparison, three of the four commercially available magnetic drapes tested in the observational study demonstrated magnetic interference on the patient’s pacemaker.

“In an era where implantation of electronic devices is on the rise, surgeons, OR nurses, hospitals and patients should be aware of the potential magnetic interferences caused by surgical magnetic drapes. This study thus confirms that the LT10G offers an important safety benefit in comparison to other available magnetic drapes” commented Richard Côté, EVP of MENODYS.

About MENODYS

MENODYS is a Canadian company specialized in the research, development and commercialization of medical technologies. www.menodys.com

LT10 Surgical Magnetic Mat

MENODYS’ LT10G Surgical Magnetic Mat is granted a US patent

Longueuil, Quebec, Canada – MENODYS announces that it has been granted a patent for its LT10G Surgical Magnetic Mat technology by the USPTO on January 12, 2016 (Patent 9,232,976 Magnetic Interference Reducing Surgical Drape).

The LT10G is the first medical technology developed and commercialized by MENODYS. Co-invented by Dr. L.-P. Fortier and Dr. V. Zaphiratos of the anaesthesiology department of the Maisonneuve-Rosemont Hospital in Montreal, Quebec, Canada, the LT10G is an innovative surgical magnetic drape that reduces the risks of magnetic interferences for patients with implanted electronic devices going through a surgical procedure.

About MENODYS

MENODYS is a Canadian company specialized in the research, development and commercialization of medical technologies. www.menodys.com

Sterile saline slush making apparatus

MENODYS launches the development of its 4th medical technology, the Sterile Saline Slush Making Apparatus and files a provisional patent

Longueuil, Quebec, Canada – MENODYS announces the filing of a provisional patent for its newest medical technology, the 4th technology in its pipeline, the sterile saline slush making apparatus.

Invented by Dr Pierre Marsolais, internal medicine specialist, intensivist and coordinator of the organ collection center of the Sacré-Coeur of Montreal Hospital, this medical technology will answer an important unmet need in the preservation of organ for transplantation in allowing the automated production of large volumes of sterile saline slush. “ This fourth medical technology in our pipeline and third with the University of Montreal is confirming the acceleration of the development of MENODYS. Our business model clearly answers the needs of clinicians, like Dr Marsolais, who are looking for a specialized industry partner in the field of medical technologies to bring their ideas to the market” said René Gosselin, President of MENODYS.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Tinninus Assessment Technology

MENODYS’s Tinnitus Assessment Technology featured in medGadget’s Ear, Nose and Throat Diagnostic and Surgical Devices Pipeline Review, 2015

Longueuil, Quebec, Canada – MENODYS and its Tinnitus Assessment Technology are featured in the Ear, Nose and Throat Diagnostic and Surgical Devices Pipeline Review, 2015 of medGadget, the web-based medical technology news source, dated September 18th 2015. Exclusively licenced to MENODYS and invented by Pr Sylvie Hébert and Philippe Fournier of the School of Speech Pathology and Audiology of the University of Montreal, the Tinnitus Assessment Technology offers audiology specialists around the world a faster and objective approach to assess the frequency spectrum and amplitude of their patient’s tinnitus. This medical technology will thus allow audiology specialists to better design the symptoms attenuation protocol of the patient’s tinnitus.

“Being part of such international market research studies is a confirmation of our business model of bringing innovative medical technology ideas to the market and for international medical device companies to take on their commercialization. We have recently completed the development and validation of the technology and we have initiated discussions with possible commercialization partners with the hope of quickly bringing this innovative approach in audiology to the growing worldwide population suffering from tinnitus”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

 

 

Tinninus Assessment Technology

MENODYS launches the clinical validation of its Tinnitus Assessment Technology

Longueuil, Quebec, Canada – MENODYS is proud to announce the launch of the clinical validation phase of its tinnitus assessment technology.

This important milestone is reached following the successful completion of prototypes enabling the assessment of tinnitus based on the developed university bench version. Invented by Pr Sylvie Hébert and Philippe Fournier of the School of Speech Pathology and Audiology at the University of Montreal, the device will offer audiology specialists around the world a rapid and innovative approach to objectively assess the frequency and amplitude of their patient’s tinnitus. This medical technology will thus allow audiology specialists to precisely design the symptom attenuation protocol for the patient’s tinnitus. The clinical validation will involve adults suffering from tinnitus and will be performed at the department of audiology of the University of Montreal, Quebec, Canada.

“We are excited with the rapid development process of this much needed medical device innovation for an important unmet need in audiology. This clinical validation will confirm the published results of this new technological concept and bring us a step closer to offering this innovation worldwide to tinnitus patients and audiology professionals”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

LT10 Surgical Magnetic Mat

The LT10G™ Surgical Magnetic Mat to be showcased at the AQLASS 2015 meeting

Longueuil, Quebec, Canada – MENODYS’s LT10G™ Surgical Magnetic Mat will be presented to the 300 participants of the Quebec Association of Logistics and Purchasing of the Healthcare Sector (AQLASS) annual meeting on June 12th in Mont-Tremblant, Quebec. “This is a tremendous opportunity for MENODYS to showcase its first commercialized medical innovation, the LT10G™, to the most important meeting of hospital buyers from the province of Quebec” said Richard Côté, Executive Vice President of MENODYS.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

About AQLASS

Founded in 1967, the AQLASS is the oldest Canadian provincial purchasing association of the healthcare sector. For more information visit: www.aqlass.org

scar-with-without-treatment

MENODYS launches a clinical proof of concept on its innovative Scar Appearance Minimizing Device

Longueuil, Quebec, Canada MENODYS is initiating a first in human clinical proof of concept with its innovative Scar Appearance Minimizing Device in patients undergoing an abdominoplasty. MENODYS has selected the Montreal Health Innovations Coordinating Center (MHICC), a division of the Montreal Heart Institute and Q&T Research, Sherbrooke, Quebec to coordinate this clinical trial to test MENODYS’ technology in 15 patients. Dr. Michel Chagnon, MD, FRCP, general surgeon, will be the principal investigator for this study. The primary objective of the study is to evaluate the benefits of the MENODYS’ device in minimizing the appearance of a scar over a period of 8 weeks of treatment with the device.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

About the Montreal Heart Institute

Founded in 1954 by Dr. Paul David, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training and prevention. It is part of the broad network of health excellence made up of Université de Montréal and its affiliated institutions. The Montreal Health Innovations Coordinating Centre (MHICC), a division of the MHI, is a full service clinical academic research organization, providing services to the academic community and to the pharmaceutical, biotechnology and medical device industries, in the fields of cardiology, neurology, oncology, dermatology, endocrinology and pharmacogenomics. www.icm-hi.org  www.micc.org

About Q&T Research

Q&T Research is an independent clinical research site with a robust expertise in Phase II-III vaccines, blood derivatives for immuno markers, moderate to severe psoriasis, Alzheimer, COPD and women/men health. The research group is made of 6 research nurses, 8 physicians, 2 lab technicians, 1 research assistant and 1 pharmacist. The group aims at reaching high quality of information gathered, meeting the recruitment target and respecting the mutually agreed timelines. www.qtresearch.com